Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes.

Colburn WA, Gottlieb AB, Koda J, Kolterman OG

Journal of clinical pharmacology1 Jan 1996Cited by 40 (Europe PMC)

PMID8932539DOI10.1002/j.1552-4604.1996.tb04147.xPepBankPUB-08932539

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialPharmacokinetics
In patients with IDDM, AC137 pharmacokinetics were linear across the studied dose range.
In plain wordsIn patients with IDDM, AC137 pharmacokinetics were linear across the tested doses.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableDose linearity
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
30-mug, 100-mug, and 300-mug · intravenous · 2-minute bolus or 2-hour infusionAs given in this study (human).
Source sentences
Summary
Pharmacokinetics were linear over the dose range studied,
2 context sentences(design, population, supporting numbers)
Summary · context
A study was conducted to evaluate the effect of 30-mug, 100-mug, and 300-mug 2-minute bolus doses and 2-hour infusion doses of AC137 (25,28,29 tripro-amylin, human) on plasma AC137 concentrations and plasma glucose and lactate responses in patients with insulin-dependent diabetes mellitus (IDDM).
Summary · context
The study design was an imbedded two-way cross-over wherein patients received placebo and active boluses in one period and placebo and active infusions in the other period.
Report a problemFND-0893253901
02HumanNon-randomized trialEfficacy outcome
In patients with IDDM, AC137 attenuated meal glucose responses in a dose- and concentration-dependent manner.
In plain wordsIn patients with IDDM, AC137 reduced meal glucose responses as dose and concentration increased.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMeal glucose response
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30-mug, 100-mug, and 300-mug · intravenous · 2-minute bolus or 2-hour infusionAs given in this study (human).
Source sentences
Summary
Pharmacokinetics were linear over the dose range studied, and attenuation of glucose and lactate responses to a mixed meal was dose and concentration dependent.
2 context sentences(design, population, supporting numbers)
Summary · context
A study was conducted to evaluate the effect of 30-mug, 100-mug, and 300-mug 2-minute bolus doses and 2-hour infusion doses of AC137 (25,28,29 tripro-amylin, human) on plasma AC137 concentrations and plasma glucose and lactate responses in patients with insulin-dependent diabetes mellitus (IDDM).
Summary · context
The study design was an imbedded two-way cross-over wherein patients received placebo and active boluses in one period and placebo and active infusions in the other period.
Report a problemFND-0893253902
03HumanNon-randomized trialEfficacy outcome
In patients with IDDM, AC137 attenuated meal lactate responses in a dose- and concentration-dependent manner.
In plain wordsIn patients with IDDM, AC137 reduced meal lactate responses as dose and concentration increased.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMeal lactate response
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30-mug, 100-mug, and 300-mug · intravenous · 2-minute bolus or 2-hour infusionAs given in this study (human).
Source sentences
Summary
Pharmacokinetics were linear over the dose range studied, and attenuation of glucose and lactate responses to a mixed meal was dose and concentration dependent.
2 context sentences(design, population, supporting numbers)
Summary · context
A study was conducted to evaluate the effect of 30-mug, 100-mug, and 300-mug 2-minute bolus doses and 2-hour infusion doses of AC137 (25,28,29 tripro-amylin, human) on plasma AC137 concentrations and plasma glucose and lactate responses in patients with insulin-dependent diabetes mellitus (IDDM).
Summary · context
The study design was an imbedded two-way cross-over wherein patients received placebo and active boluses in one period and placebo and active infusions in the other period.
Report a problemFND-0893253903
04HumanNon-randomized trialEfficacy outcome
In patients with IDDM, the PK/PD model indicated greater glucose response attenuation with AC137 infusion than with equal bolus doses.
In plain wordsIn patients with IDDM, modelling indicated that AC137 infusion reduced glucose responses more than equal bolus doses.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMeal glucose response by administration mode
Study
n: not reported in source
Comparator
Same AC137 dose as bolus
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30-mug, 100-mug, and 300-mug · intravenous · 2-hour infusion versus 2-minute bolusAs given in this study (human).
Source sentences
Summary
The results of the PK/PD model indicate that the attenuation of glucose and lactate responses was greater after AC137 infusion doses than after the same doses given as a bolus.
2 context sentences(design, population, supporting numbers)
Summary · context
A study was conducted to evaluate the effect of 30-mug, 100-mug, and 300-mug 2-minute bolus doses and 2-hour infusion doses of AC137 (25,28,29 tripro-amylin, human) on plasma AC137 concentrations and plasma glucose and lactate responses in patients with insulin-dependent diabetes mellitus (IDDM).
Summary · context
The study design was an imbedded two-way cross-over wherein patients received placebo and active boluses in one period and placebo and active infusions in the other period.
Report a problemFND-0893253904
05HumanNon-randomized trialEfficacy outcome
In patients with IDDM, the PK/PD model indicated greater lactate response attenuation with AC137 infusion than with equal bolus doses.
In plain wordsIn patients with IDDM, modelling indicated that AC137 infusion reduced lactate responses more than equal bolus doses.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMeal lactate response by administration mode
Study
n: not reported in source
Comparator
Same AC137 dose as bolus
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30-mug, 100-mug, and 300-mug · intravenous · 2-hour infusion versus 2-minute bolusAs given in this study (human).
Source sentences
Summary
The results of the PK/PD model indicate that the attenuation of glucose and lactate responses was greater after AC137 infusion doses than after the same doses given as a bolus.
2 context sentences(design, population, supporting numbers)
Summary · context
A study was conducted to evaluate the effect of 30-mug, 100-mug, and 300-mug 2-minute bolus doses and 2-hour infusion doses of AC137 (25,28,29 tripro-amylin, human) on plasma AC137 concentrations and plasma glucose and lactate responses in patients with insulin-dependent diabetes mellitus (IDDM).
Summary · context
The study design was an imbedded two-way cross-over wherein patients received placebo and active boluses in one period and placebo and active infusions in the other period.
Report a problemFND-0893253905
06HumanNon-randomized trialEfficacy outcome
In patients with IDDM, the 300-mug AC137 infusion essentially negated the meal glucose response.
In plain wordsIn patients with IDDM, the 300-mug AC137 infusion nearly eliminated the meal glucose response.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMeal glucose response at high infusion dose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
300-mug · intravenous · 2 hoursAs given in this study (human).
Source sentences
Summary
Glucose and lactate responses to a mixed meal were essentially negated by the 300-mug infusion dose.
2 context sentences(design, population, supporting numbers)
Summary · context
A study was conducted to evaluate the effect of 30-mug, 100-mug, and 300-mug 2-minute bolus doses and 2-hour infusion doses of AC137 (25,28,29 tripro-amylin, human) on plasma AC137 concentrations and plasma glucose and lactate responses in patients with insulin-dependent diabetes mellitus (IDDM).
Summary · context
The study design was an imbedded two-way cross-over wherein patients received placebo and active boluses in one period and placebo and active infusions in the other period.
Report a problemFND-0893253906
07HumanNon-randomized trialEfficacy outcome
In patients with IDDM, the 300-mug AC137 infusion essentially negated the meal lactate response.
In plain wordsIn patients with IDDM, the 300-mug AC137 infusion nearly eliminated the meal lactate response.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMeal lactate response at high infusion dose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
300-mug · intravenous · 2 hoursAs given in this study (human).
Source sentences
Summary
Glucose and lactate responses to a mixed meal were essentially negated by the 300-mug infusion dose.
2 context sentences(design, population, supporting numbers)
Summary · context
A study was conducted to evaluate the effect of 30-mug, 100-mug, and 300-mug 2-minute bolus doses and 2-hour infusion doses of AC137 (25,28,29 tripro-amylin, human) on plasma AC137 concentrations and plasma glucose and lactate responses in patients with insulin-dependent diabetes mellitus (IDDM).
Summary · context
The study design was an imbedded two-way cross-over wherein patients received placebo and active boluses in one period and placebo and active infusions in the other period.
Report a problemFND-0893253907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.